Biologic mechanisms of 89SrCl2 incorporation into type I collagen during bone mineralization

Journal of Nuclear Medicine

Volumn 41, Issue 1, 2000, Pages 183-188

  Davis, Julie ^b   Cook, Neil D ^b   Pither, Richard J ^a  

^a GENERAL ELECTRIC COMPANY   (United States)

^b NONE

Author keywords

Bone mineralization; Bone neoplasms; Collagen; Radiopharmaceutical; Strontium radioisotope

Indexed keywords

COLLAGEN TYPE 1; STRONTIUM 89; STRONTIUM CHLORIDE; CALCIUM; CALCIUM CHLORIDE; COLLAGEN; STRONTIUM;

ANIMAL CELL; ARTICLE; BONE METASTASIS; BONE MINERALIZATION; BONE PAIN; CANCER PALLIATIVE THERAPY; CELLULAR DISTRIBUTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; ANIMAL; BONE; BONE TUMOR; CELL CULTURE; CELL LINE; COMPARATIVE STUDY; HUMAN; MALE; METABOLISM; METASTASIS; MOUSE; PALLIATIVE THERAPY; PATHOLOGY; PROSTATE TUMOR; TIME;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CALCIFICATION, PHYSIOLOGIC; CALCIUM CHLORIDE; CALCIUM RADIOISOTOPES; CELL LINE; COLLAGEN; HUMANS; MALE; MICE; PALLIATIVE CARE; PROSTATIC NEOPLASMS; STRONTIUM; STRONTIUM RADIOISOTOPES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033621790     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med. 1993;20:66-74.
2. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Akery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med. 1988;29:549-557.
3. Ackery D, Yardley J. Radionuclide-targeted therapy for the management of metastatic bone pain. Semin Oncol. 1993;20:27-31.
4. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol. 1995;18:51-64.
5. Graves R, Davies R, Brophy G, O'Beirne G, Cook N. Non-invasive, real-time method for the examination of thymidine uptake events: application of the method to V-79 cell synchrony studies. Anal Biochem. 1997;248:251-257.
6. Franceschi RT, Iyer BS. Effects of ascorbic acid on collagen matrix formation and osteoblast differentiation in murine MC3T3-El cells. J Bone Miner Res. 1994;9: 843-854.
7. Chung C-H, Golub EE, Forbes E, Tokuoka T, Shapiro IM. Mechanism of action of β-glycerophosphate on bone cell mineralisation. Calcif Tissue Int. 1992;51: 305-311.
8. Marsh ME, Munne AM, Vogel JJ, Cui Y, Francheschi RT. Mineralization of bone-like extracellular matrix in the absence of functional osteoblasts. J Bone Miner Res. 1995;10:1635-1643.
9. Bessey OA, Lowry OH, Brock MJ. A method for the rapid determination of alkaline phosphatase with five cubic millimeters of serum. J Biol Chem. 1946;164:321-329.
10. Keeping HS, Lo S, Akerley WL, et al. Differential uptake and retention of strontium-89 in human osteoblast and bone metastatic prostate cancer cell lines. Poster presented at: 7th Prouts Neck Meeting on Prostate Cancer; October 16-20, 1996; Prouts Neck, ME.
11. Casser-Bette M, Murray AB, Closs EI, Erfle V, Schmidt J. Bone formation by osteoblast-like cells in a three-dimensional cell culture. Calcif Tissue Int. 1990;46:46-56.
12. Sudo H, Kodama H, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol. 1983;96:191-198.
13. Silberstein EB. The treatment of painful osteoblastic metastases: what can we expect from nuclear oncology. J Nucl Med. 1994;35:1994-1995.
14. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone. 1995;17(suppl):101S-105S.
15. Edwards GK, Santoro J, Taylor A Jr. Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89. J Nucl. Med. 1994;35:992-993.
16. Ben-Josef E, Maughan RL, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation. Nucl Med Commun. 1995;16:457-463.
17. Ben-Josef E, Maughan RL, Vasan S. A direct measurement of strontium-89 activity in bone metastases. Nucl Med Commun. 1995;16:452-456.
18. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostate carcinoma. J Nucl Med. 1992;33:1316-1323.